The Role of Local Angiotensin II/Angiotensin Type 1-receptor Mechanisms in Adipose Tissue Dysfunction to Promote Pancreatic Cancer

Overview

Journal Curr Cancer Drug Targets

Publisher Bentham Science Publishers

Specialty Oncology

Date 2024 Feb 13

PMID 38347780

Authors

Rozita Khodashahi

Fatemeh Beiraghdar

Gorgon A Ferns

Kiayash Ashrafzadeh

Mohsen Aliakbarian

Mohammad-Hassan Arjmand

Affiliations

Soon will be listed here.

Abstract

Obesity and adipose tissue dysfunction are important risk factors for pancreatic cancer. Pancreatic cancer is one of the most lethal cancers globally. The renin-angiotensin system (RAS) is expressed in many tissues, including adipose tissue. Dysregulation of angiotensin II and angiotensin II receptors in adipose tissue through the activation of different signaling pathways leads to adipose tissue dysfunction, including insulin resistance, adipose tissue inflammation, adipocytokines secretion, and metabolic alterations. The pathogenesis of pancreatic cancer remains uncertain. However, there is evidence that dysregulation of local angiotensin II in adipose tissue that occurs in association with obesity is, in part, responsible for the initiation and progression of pancreatic cancer. Due to the role of local angiotensin II in the dysfunction of adipose tissue, angiotensin receptor blockers may be considered a new therapeutic strategy in the amelioration of the complications related to adipose tissue dysfunction and prevention of pancreatic cancer. This review aims to consider the biological roles of local angiotensin II and angiotensin II receptors in adipose tissue dysfunction to promote pancreatic cancer progression with a focus on adipose tissue inflammation and metabolic reprogramming.

References

Martyniak A, Tomasik P . A New Perspective on the Renin-Angiotensin System. Diagnostics (Basel). 2023; 13(1). PMC: 9818283. DOI: 10.3390/diagnostics13010016. View

Kanugula A, Kaur J, Batra J, Ankireddypalli A, Velagapudi R . Renin-Angiotensin System: Updated Understanding and Role in Physiological and Pathophysiological States. Cureus. 2023; 15(6):e40725. PMC: 10283427. DOI: 10.7759/cureus.40725. View

Iwai M, Horiuchi M . Role of renin-angiotensin system in adipose tissue dysfunction. Hypertens Res. 2009; 32(6):425-7. DOI: 10.1038/hr.2009.55. View

Pahlavani M, Kalupahana N, Ramalingam L, Moustaid-Moussa N . Regulation and Functions of the Renin-Angiotensin System in White and Brown Adipose Tissue. Compr Physiol. 2017; 7(4):1137-1150. PMC: 7561006. DOI: 10.1002/cphy.c160031. View

Shiuchi T, Iwai M, Li H, Wu L, Min L, Li J . Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension. 2004; 43(5):1003-10. DOI: 10.1161/01.HYP.0000125142.41703.64. View

Tomono Y, Iwai M, Inaba S, Mogi M, Horiuchi M . Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models. Am J Hypertens. 2008; 21(2):206-12. DOI: 10.1038/ajh.2007.50. View

Iyengar N, Gucalp A, Dannenberg A, Hudis C . Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation. J Clin Oncol. 2016; 34(35):4270-4276. PMC: 5562428. DOI: 10.1200/JCO.2016.67.4283. View

Quail D, Dannenberg A . The obese adipose tissue microenvironment in cancer development and progression. Nat Rev Endocrinol. 2018; 15(3):139-154. PMC: 6374176. DOI: 10.1038/s41574-018-0126-x. View

Khandekar M, Cohen P, Spiegelman B . Molecular mechanisms of cancer development in obesity. Nat Rev Cancer. 2011; 11(12):886-95. DOI: 10.1038/nrc3174. View

10.

Laurent V, Toulet A, Attane C, Milhas D, Dauvillier S, Zaidi F . Periprostatic Adipose Tissue Favors Prostate Cancer Cell Invasion in an Obesity-Dependent Manner: Role of Oxidative Stress. Mol Cancer Res. 2019; 17(3):821-835. DOI: 10.1158/1541-7786.MCR-18-0748. View

11.

Okumura T, Ohuchida K, Sada M, Abe T, Endo S, Koikawa K . Extra-pancreatic invasion induces lipolytic and fibrotic changes in the adipose microenvironment, with released fatty acids enhancing the invasiveness of pancreatic cancer cells. Oncotarget. 2017; 8(11):18280-18295. PMC: 5392327. DOI: 10.18632/oncotarget.15430. View

12.

Duong M, Geneste A, Fallone F, Li X, Dumontet C, Muller C . The fat and the bad: Mature adipocytes, key actors in tumor progression and resistance. Oncotarget. 2017; 8(34):57622-57641. PMC: 5593672. DOI: 10.18632/oncotarget.18038. View

13.

Liu R, Nikolajczyk B . Tissue Immune Cells Fuel Obesity-Associated Inflammation in Adipose Tissue and Beyond. Front Immunol. 2019; 10:1587. PMC: 6653202. DOI: 10.3389/fimmu.2019.01587. View

14.

Lu J, Zhao J, Meng H, Zhang X . Adipose Tissue-Resident Immune Cells in Obesity and Type 2 Diabetes. Front Immunol. 2019; 10:1173. PMC: 6540829. DOI: 10.3389/fimmu.2019.01173. View

15.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

16.

Almutlaq M, Alamro A, Alamri H, Alghamdi A, Barhoumi T . The Effect of Local Renin Angiotensin System in the Common Types of Cancer. Front Endocrinol (Lausanne). 2021; 12:736361. PMC: 8446618. DOI: 10.3389/fendo.2021.736361. View

17.

Brocco D, Florio R, De Lellis L, Veschi S, Grassadonia A, Tinari N . The Role of Dysfunctional Adipose Tissue in Pancreatic Cancer: A Molecular Perspective. Cancers (Basel). 2020; 12(7). PMC: 7408631. DOI: 10.3390/cancers12071849. View

18.

Kalupahana N, Claycombe K, Moustaid-Moussa N . (n-3) Fatty acids alleviate adipose tissue inflammation and insulin resistance: mechanistic insights. Adv Nutr. 2012; 2(4):304-16. PMC: 3125680. DOI: 10.3945/an.111.000505. View

19.

Wellen K, Hotamisligil G . Obesity-induced inflammatory changes in adipose tissue. J Clin Invest. 2003; 112(12):1785-8. PMC: 297006. DOI: 10.1172/JCI20514. View

20.

Karlsson C, Lindell K, Ottosson M, Sjostrom L, Carlsson B, Carlsson L . Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab. 1998; 83(11):3925-9. DOI: 10.1210/jcem.83.11.5276. View